Cargando…

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma

BACKGROUND: Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Røe, Oluf Dimitri, Szulkin, Adam, Anderssen, Endre, Flatberg, Arnar, Sandeck, Helmut, Amundsen, Tore, Erlandsen, Sten Even, Dobra, Katalin, Sundstrøm, Stein Harald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414492/ https://www.ncbi.nlm.nih.gov/pubmed/22905093 http://dx.doi.org/10.1371/journal.pone.0040521

Ejemplares similares

Genome-Wide Profile of Pleural Mesothelioma versus Parietal and Visceral Pleura: The Emerging Gene Portrait of the Mesothelioma Phenotype
por: Røe, Oluf Dimitri, et al.
Publicado: (2009)

Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry
por: Sandeck, Helmut P, et al.
Publicado: (2010)

A framework for significance analysis of gene expression data using dimension reduction methods
por: Gidskehaug, Lars, et al.
Publicado: (2007)

Genome‐wide analysis of the oxyntic proliferative isthmus zone reveals ASPM as a possible gastric stem/progenitor cell marker over‐expressed in cancer
por: Vange, Pål, et al.
Publicado: (2015)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
por: Szulkin, Adam, et al.
Publicado: (2013)

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
por: Szulkin, Adam, et al.
Publicado: (2014)

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
por: Nilsonne, Gustav, et al.
Publicado: (2009)

Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review
por: Panou, Vasiliki, et al.
Publicado: (2020)

Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
por: Røe, Oluf Dimitri, et al.
Publicado: (2015)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
por: Forde, Patrick M., et al.
Publicado: (2021)

Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
por: Kutuk, Tugce, et al.
Publicado: (2022)

Inhibitors of cytoskeletal dynamics in malignant mesothelioma
por: Reis, Katarina, et al.
Publicado: (2020)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
por: Qin, Yiyang, et al.
Publicado: (2017)

Cytoskeletal Organization Correlates to Motility and Invasiveness of Malignant Mesothelioma Cells
por: Keller, Maureen, et al.
Publicado: (2021)

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience
por: Bearz, Alessandra, et al.
Publicado: (2012)

Interplay of non-coding RNAs and approved antimetabolites such as gemcitabine and pemetrexed in mesothelioma
por: Biersack, Bernhard
Publicado: (2018)

Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines
por: Monica, Valentina, et al.
Publicado: (2016)

Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma
por: Youk, Jeonghwan, et al.
Publicado: (2017)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021)

ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment
por: Ponce, Santiago, et al.
Publicado: (2023)

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
por: Barbier, Michaela Carla, et al.
Publicado: (2023)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
por: Goricar, Katja, et al.
Publicado: (2014)

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin
por: Kim, Jung Sun, et al.
Publicado: (2017)

Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova, Emanuela, et al.
Publicado: (2019)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma
por: Darai-Ramqvist, Eva, et al.
Publicado: (2013)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2020)

The duration of gastrin treatment affects global gene expression and molecular responses involved in ER stress and anti-apoptosis
por: Selvik, Linn-Karina M, et al.
Publicado: (2013)

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
por: Severi, Leda, et al.
Publicado: (2018)

Adjuvant Bidirectional Chemotherapy with Intraperitoneal Pemetrexed Combined with Intravenous Cisplatin for Diffuse Malignant Peritoneal Mesothelioma
por: Bijelic, Lana, et al.
Publicado: (2012)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

Synergistic anti-tumor effect of bullfrog sialic acid-binding lectin and pemetrexed in malignant mesothelioma
por: Satoh, Toshiyuki, et al.
Publicado: (2017)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

High plasma exposure to pemetrexed leads to severe hyponatremia in patients with advanced non small cell lung cancer receiving pemetrexed-platinum doublet chemotherapy
por: Gota, Vikram, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0h1d9japu9i0o4k9t4v14r9d80